Introduction
Cross-talk between hematopoietic cells with non-hematopoietic marrow cells in myelofibrosis (MF) contributes to distinctive marrow micro-environmental changes which likely comprise the function of specific marrow niches which support normal hematopoiesis (1) (2) (3) . MF cells elaborate cytokines which contribute to the development of marrow fibrosis, increased microvessel density and osteosclerosis (3) . These cytokines affect marrow mesenchymal cells that are not involved by the malignant process (3) (4) (5) (6) (7) (8) (9) .
Recently, neutrophil gelatinase-associated lipocalin (LCN2) has been implicated in the pathobiology of myeloproliferative neoplasms (MPNs)(10-13). LCN2 promotes the proliferation of the malignant clone in chronic myeloid leukemia (14). In addition, LCN2 gene expression has been reported to be increased in CD34 + cells isolated from primary MF (PMF) as well as PV patients while LCN2 levels were elevated in the plasma of MPN patients (10-13). Furthermore, Kagoya and coworkers in a mouse model demonstrated that JAK2V617F positive cells elaborate LCN2 resulting in DNA damage in neighboring normal cells as well as cells belonging to the malignant clone by generating reactive oxygen species (11). We, therefore, further examined the role that LCN2 might play in MPNs
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Material and Method

Specimen collection
Patient samples were collected at the Icahn School of Medicine at Mount Sinai (ISMMS).
Written informed consent was obtained from patients according to guidelines established by the Institutional Review Board of the ISMMS, New York, NY. All patients met the World Health Organization diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET) and PMF (1) . CD34 + cells were isolated using a human CD34 + cell selection kit (StemCell Technologies, Vancouver, BC, Canada), T and B cell depleted MNC were isolated using a human lymphocyte selection kit (StemCell Technologies). The severity of MF in 70 patients was assessed using prognostic parameters utilized for the development of the Dynamic International Prognostic Scoring System (DIPPS)(15-16).
Preparation of BM adherent cells
Human BM mononuclear cells (MNC) were cultured in mesenchymal stem cell growth medium (MSCGM) (Lonza) at a density of 2-5X10 4 /ml in culture flasks or dishes. The cells that remained in suspension were removed by completely changing the medium at the time adherent cell (AC) layers were formed. The medium was changed twice weekly by replacing half of the medium with fresh MSCGM. Studies were performed with ACs that had not been passaged more than 4 times.
Cell proliferation assays
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CD34
+ cells were cultured with Serum-Free Medium (SFEM)(StemCell Technologies)
containing stem cell factor (SCF), thrombopoietin (TPO), fms-like tyrosine kinase 3 ligand (Flt-3L) and interleukin-3 (IL-3) (R&D Systems Minneapolis, MN) with and without LCN2 (Sigma, St. Louis, MO). Cell viability was determined using trypan-blue (Sigma). The proportion of CD34 + cells was measured flow cytometrically after staining with an anti-CD34 antibody (BD Biosciences, San Jose, CA). AC proliferation was determined using the PrestoBlue cell viability reagent (Life Technologies, CA).
JAK2V617F genotyping of hematopietic colonies
CD34
+ cells were plated in 30mm dishes containing 1 mL SFEM with 1.1% methylcellulose, to which SCF, TPO, Flt-3L, granulocyte macrophage-colony stimulating factor (GM-CSF) and IL-3 and EPO were added with or without LCN2 (17). Individual colonies were randomly plucked and JAK2V617F was detected using nested allele-specific PCR (17).
Flow cytometric analyses
Cells were collected and washed with MACS buffer, and were stained with anti-CD34 antibody, annexin-V (BD Biosciences) or LCN2 receptor antibody (Abcam, Cambridge, MA) directly. For intracellular staining, cells were fixed with 4% formaldehyde and permeabilized, and then stained with antibody to γ H2AX, or adichlorofluoresendiacetate (DCFDA) (Abcam) to evaluate the ROS activity. Data were acquired using a FACS Caliber analyzer (BD Biosciences).
Immunofluorescent and immunohistochemical staining
Cells were fixed with 4% formaldehyde, permeabilized, and then stained with primary antibodies. The primary antibodies were visualized with AlexaFluor 546-or AlexaFluor 488- 
BM mesenchymal stem cell differentiation assays
BM AC cells were cultured in MSCGM with or without LCN2 for at least ten days, and then with media designed to favor either adipogenic or osteogenic differentiation (R & D Systems).
The cells then were fixed and underwent immunostaining.
Isolation of RNA and qRT-PCR
BM ACs were cultured with MSCGM alone or medium containing LCN2 for 1 to 10 days. Total RNA was extracted from the ACs using RNeasy kit (Qiagen, Valencia, CA). cDNA was reverse transcribed using EcoDry Premix kit (Clontech). The BMP2, COL1A1, OPG, PPARγ, RUNX2, TGF-β, VEGF and GAPDH genes were evaluated by qPCR which was performed using SYBR® Green-based RT² qPCR Master Mixes from Qiagen and the Realplex thermocycler (Eppendorf).
Statistical methods
Non-parametric Wilcoxon Rank Sum Tests were used to assess two group differences; nonparametric Kruskal Wallis analysis of variance F tests were used to assess multi-group
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From 8 differences. Correlations between LCN2 and hematologic parameters were determined using non-parametric Spearman correlation coefficients. ANOVA F-tests were used to evaluate differences between cell samples. All pairwise comparisons were performed with Sidak correction in SPSS Version 20. p-values less than 0.05 after adjustment were considered statistically significant. Statistical analysis was performed using SAS 9.3.
A more detailed material and methods section has been provided as a supplement.
Results
LCN2 levels are elevated in MF plasma and MF MNC conditioned media.
PV, ET and PMF plasma LCN2 levels were significantly greater than normal control plasmas (p<0.0001) (Figure 1a) . PMF plasmas contained significantly higher levels of LCN2 (median=93.8ng/ml, range: 6.9-329.0) than PV (median=54.8ng/ml, range: 2.7-268.0) or ET (median=47.4ng/ml, range: 13.3-167.7) plasmas (p=0.0175). Furthermore, plasma LCN2 levels from patients with PV-MF (median=160.7ng/ml, range: 9.9-281.1) as well as ET-MF (median=93.1ng/ml, range: 31.7-173.5) were significantly greater than that present in PV or ET plasmas, respectively, (p=0.0002 and p=0.0175, respectively)( Figure 1a ). An inverse relationship between both patient hemoglobin levels (p<0.0001) (Figure 1b ) and platelet counts and LNC2 levels was observed (p=0.0044) (Figure 1c) . However, the plasma LCN2 levels were not significantly different in those patients that had more severe degrees of MF (Figure 1d ). The levels of plasma LCN2 were not related to the degree of elevation of number of WBCs ( Figure   S1 ), the type of treatment received ( Figure S2 Figure 3a) . Also, LCN2 decreased the numbers of assayable normal marrow CFU-GM-but not BFU-E (p=0.001 and p>0.05, respectively, Figure 3b and Table S1 ). By contrast, LCN2 did not inhibit but rather promoted MF BFU-E-and CFU-GM-derived colony formation (p=0.02 and p=0.009 respectively, Figure 3c and Table S2 ). Similarly, LCN2 treatment significantly decreased the numbers of CFU-GM-derived colonies generated from normal G-CSF mobilized peripheral blood CD34 + cells (p=0.03 and p=0.047, respectively, Figure S6 and Table S3 Figure 4a and Table S4 ). We then assessed if reactive oxygen species (ROS) were 
Phenotypic and functional analysis of LCN2 primed adherent cells and mesenchymal stem cells (MSC)
Normal MAC in both control cultures and cultures containing LCN2 were CD45 -and CD34 -, but expressed vimentin, In this report, the levels of LCN2 in the plasmas of MF patients (PMF, PV-MF and ET-MF)
were each shown to be greater than that present in normal control plasma; findings which extends the observations of others (10-13). Furthermore, the LCN2 levels present in the MF plasmas were 2-3 fold greater than that observed in patients with proliferative MPNs (PV and ET) providing a possible link between increased LCN2 levels and progression to MF. An inverse relationship between plasma LCN2 levels and Hgb levels and platelet counts but not WBC numbers in MPN patients was observed, suggesting that LCN2 might be related to the development of anemia and thrombocytopenia. The degree of increase in plasma LCN2 levels in patients was not related to gender, age, type of treatment received or the severity of MF.
Importantly, MF MNC CM contained elevated LCN2 levels and LCN2 mRNA expression levels were higher in lymphocyte depleted MF MNC cells. LCN2 was localized to myeloid cells within MF marrow cells. Although LCN2 transcripts were documented in this report to be detectable in normal and MF CD34 + cells (12, 13), LCN2 synthesis has been previously shown to occur (11) who observed that LCN2 inhibited both normal as well as JAK2V617F positive hematopoiesis.
These discrepancies can be attributed to cells from different species being studied or the phase of MPN examined in the two studies being different (PV versus MF). Barosi and co-workers observed in a longitudional study of MF patients a consistent rate of transformation from a heterozygous to a homozygous JAK2V617F mutational status which was associated with disease progression (39) . In the present report, the addition of LCN2 to MF CD34 + cells resulted in an increase in the proportion of hematopoietic colonies that were homozygous rather than heterozygous for JAK2V617 indicating that LCN2 favors the persistence of JAK2V617F homozygous rather than JAK2V617F heterozygous or JAK2 wild type progenitor cells.
The inhibitory effect of MF CM on normal hematopoiesis was observed to be independent of the JAK2V617 status of the MF MNC donor. Kagoya and co-workers(11) have reported that increased LCN2 levels were also present in MPN patient plasmas with calreticulin as well as We demonstrated that normal as well as MF MSCs express the LCN2 receptor and that LCN2 affects MSCs by promoting the generation of ROS. ROS are well known to have diverse biological consequences which are tissue specific (54-57). ROS has also been implicated previously as a determinant of MSC behavior (58-61) in cancer patients. We document that a ROS inhibitor not only blocked BM MSC proliferation, but also reduced the expression of genes associated with osteoblastic differentiation. These data are somewhat surprising since ROS has previously been reported to reduce adherence and adipocyte differentiation of rat MSCs(62-63).
These discrepancies can be attributed to either differences in the responses of rat and human 
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